immuno-oncology

Moderna ESMO

Biotech

Merck-Moderna vaccine data spur talk of Keytruda-like impact

As the dust settles on data that added $45 billion to Moderna’s market cap, analysts have begun to ask if use of the vaccine be as broad as Keytruda.

Nick Paul Taylor Aug 20, 2026 9:25am

ESMO AstraZeneca

AstraZeneca ends phase 3 cancer trial as bispecific underwhelms

Aug 17, 2026 4:45am

Person throwing piece of paper into full waste bin

Fierce Pharma

Nature retracts provocative PD-1 time-of-day study

Jun 24, 2026 11:00am

Golfer devastated after just barely missing a putt

Regeneron rocked by failure as melonama drug can't beat Keytruda

May 18, 2026 4:40am

green light go go ahead advance yes streetlight

Inhibrx’s OX40-Keytruda combo shows promise in early ph. 2 data

May 11, 2026 10:06am

A wolf that looks sad

Werewolf weighs sale or merger as cash reserves whimper

Feb 24, 2026 5:23pm